



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gentz et al.

Application Serial No 09/006,352

Art Unit: 1646

Filed: January 13, 1998

Examiner: O'Hara, E.

For: Tumor Necrosis Factor  
Receptors  $6\alpha$  &  $6\beta$

Atty Docket No.: PF454

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Amendments are shown in boldfaced text. Deletions are indicated by strikeout and insertions are indicated by underlining.

*In the claims:*

Claims 118-159, 286, 288-290, 293, 294, 296, and 298-301 have been cancelled without prejudice or disclaimer.

Claims 31, 47, 56, 63, 79, 95, 109, 291, 292, 302, 304, and 305 have been replaced with the following amended claims:

31. (Amended) The nucleic acid molecule of claim 24 **further** comprising a nucleotide sequence heterologous to SEQ ID NO:1.

47. (Thrice Amended) The nucleic acid molecule of claim 44 that **further** comprises a nucleotide sequence heterologous to SEQ ID NO:1.

56. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding the full-length polypeptide encoded by the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810;

(b) a nucleotide sequence encoding the full-length polypeptide, lacking the N-terminal methionine, which is encoded by the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810;

(c) a nucleotide sequence encoding the mature polypeptide encoded by the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810;

(d) a nucleotide sequence encoding the soluble extracellular domain encoded by the cDNA contained in clone HPHA52 ~~or clone HTPCH84~~ as deposited with the ATCC as accession number 97810, respectively; and

(e) a nucleotide sequence that is the complement of (a), (b), (c), or (d).

63. (Amended) The nucleic acid molecule of claim 59 **further** comprising a nucleotide sequence heterologous to the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810;

79. (Amended) The nucleic acid molecule of claim 75 that **further** comprises a nucleotide sequence heterologous to the cDNA contained in clone HPHA52 as deposited with the ATCC as accession number 97810.

95. (Amended) The nucleic acid molecule of claim 88 **further** comprising a nucleotide sequence heterologous to SEQ ID NO:1.

109. (Amended) The nucleic acid molecule of claim 104 **further** comprising a nucleotide sequence heterologous to said cDNA clone.

291. (Amended) An isolated polynucleotide comprising a nucleotide sequence that **has is** at least **90% identity 95% identical** to a nucleotide sequence encoding **the polypeptide amino acid residues 31-300** of SEQ ID NO:2 **wherein said polynucleotide encodes a polypeptide that binds Fas ligand.**

292. (Amended) An isolated polynucleotide comprising a nucleotide sequence that ~~has~~ is at least 95% ~~identity-identical~~ to a nucleotide sequence encoding ~~the polypeptide amino acid residues 31-283~~ of SEQ ID NO: 2 wherein said polynucleotide encodes a polypeptide that binds Fas ligand.

302. (Amended) ~~A DNA or RNA molecule comprising an~~ An expression vector ~~wherein said expression vector is capable of producing a TR6 $\alpha$  polypeptide of SEQ ID NO:2 wherein said expression vector comprises for the production of a polypeptide comprising amino acids 31-300 of SEQ ID NO:2 comprising a polynucleotide that which encodes the polypeptide amino acids 31-300 of SEQ ID NO:2 and a control region operatively linked to operably associated with a regulatory element that controls expression of~~ said polynucleotide, ~~when said expression vector is present in a compatible host cell.~~

304. (Amended) A ~~process~~ method of for producing a TR6 $\alpha$  polypeptide comprising amino acids 31-300 of SEQ ID NO:2, comprising culturing ~~a~~ the host cell of claim 303 ~~and~~ under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

305. (Amended) A process for producing a cell which produces a TR6 $\alpha$  polypeptide comprising amino acids 31-300 of SEQ ID NO:2, comprising transforming or transfecting a host cell with the expression vector of claim 302 such that the host cell, under appropriate culture conditions, produces said polypeptide.